Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) Director Bvf Partners L. P/Il bought 10,100 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were purchased at an average cost of $14.00 per share, with a total value of $141,400.00. Following the acquisition, the director now directly owns 2,036,860 shares of the company’s stock, valued at approximately $28,516,040. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Kymera Therapeutics stock traded down $0.70 during midday trading on Tuesday, reaching $14.18. The company had a trading volume of 592,319 shares, compared to its average volume of 534,474. Kymera Therapeutics, Inc. has a fifty-two week low of $13.62 and a fifty-two week high of $69.12. The stock has a fifty day moving average price of $31.57 and a 200 day moving average price of $42.98. The firm has a market cap of $733.45 million, a PE ratio of -5.72 and a beta of 2.20.
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.04). Kymera Therapeutics had a negative net margin of 194.23% and a negative return on equity of 30.40%. The business had revenue of $9.62 million during the quarter, compared to analyst estimates of $18.66 million. During the same period last year, the firm posted ($0.29) earnings per share. Kymera Therapeutics’s quarterly revenue was down 48.6% compared to the same quarter last year. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.58 earnings per share for the current fiscal year.
A number of brokerages recently commented on KYMR. Piper Sandler decreased their price target on Kymera Therapeutics from $91.00 to $43.00 and set an “overweight” rating on the stock in a research report on Monday. Wells Fargo & Company began coverage on Kymera Therapeutics in a research report on Thursday, February 10th. They issued an “overweight” rating and a $62.00 target price on the stock. B. Riley decreased their target price on Kymera Therapeutics from $67.00 to $50.00 in a research report on Wednesday, May 4th. JPMorgan Chase & Co. began coverage on Kymera Therapeutics in a research report on Thursday, March 10th. They issued a “neutral” rating and a $44.00 target price on the stock. Finally, Morgan Stanley decreased their target price on Kymera Therapeutics from $68.00 to $66.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 2nd. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $64.00.
Kymera Therapeutics Company Profile (Get Rating)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.